MINNEAPOLIS / May 08, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025.
2025 RBC Capital Markets Global Healthcare Conference
Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference.
H.C. Wainwright 3rd Annual BioConnect Conference
Tuesday, May 20th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8be4c8-bb67-420a-b0a3-cf76483d9ff3. A replay will also be posted in the Investor Relations section of the Company’s website at www.diamedica.com.
22nd Annual Craig-Hallum Institutional Investor Conference
Wednesday, May 28, 2025 - Minneapolis, Minnesota. Management will be available for one-on-one meetings throughout the day.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.
| Last Trade: | US$3.98 |
| Daily Change: | 0.16 4.19 |
| Daily Volume: | 109,231 |
| Market Cap: | US$170.180M |
May 13, 2025 March 17, 2025 February 20, 2025 February 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
